AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23896830 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon inhalation combined with mild therapeutic hypothermia (target concentration of at least 40%) (n=16)
Number of subjects: 36
Study 23896830 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon inhalation combined with mild therapeutic hypothermia (n=16)
Number of subjects: 36
Study 23896830 — intervention group
Group type: COMPARATOR
Intervention: Both groups (n=33 total evaluable patients)
Number of subjects: 36
Study 20795925 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-led progressive resistance training program (6 exercises using weight machines, performed twice a week for 10 weeks, 3 sets of 12 repetitions or until fatigue)
Number of subjects: 23
Study 20795925 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 23
Study 17703101 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test at a concentration of 1 mg/ml
Number of subjects: 29
Study 17703101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal test at a concentration of 0.1 mg/ml
Number of subjects: 29
Study 17703101 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test administered before chemotherapy
Number of subjects: 29
Study 17140177 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin combinations (cyanocobolamid, folic acid, and pyridoxine)
Number of subjects: 0
Study 17140177 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14727246 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with weekly carboplatin/paclitaxel and daily subcutaneous amifostine
Number of subjects: 0
Study 14727246 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy with weekly carboplatin/paclitaxel without daily subcutaneous amifostine
Number of subjects: 0
Study 9878932 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirudin (r-hirudin)
Number of subjects: 11142
Study 9878932 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 11142
Study 9878932 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation
Number of subjects: 11142
Study 9878932 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST-segment elevation
Number of subjects: 11142
Study 7720448 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and Gentacoll
Number of subjects: 107
Study 7720448 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (control)
Number of subjects: 107
Study 7720448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 7720448 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 107
Study 7720448 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentacoll and Clindamycin
Number of subjects: 107
Study 2116817 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 68
Study 2116817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 6892751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose free milk
Number of subjects: 341
Study 6892751 — intervention group
Group type: COMPARATOR
Intervention: Regular milk
Number of subjects: 341
Study 6892751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose enriched milk
Number of subjects: 341
Study 31832636 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital schistosomiasis (egg positive and/or hematuria positive)
Number of subjects: 4437
Study 31576651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined video game distraction and anesthesia mask exposure and shaping intervention
Number of subjects: 128
Study 31576651 — intervention group
Group type: COMPARATOR
Intervention: Conventional preoperative preparation (Control)
Number of subjects: 128
Study 29653193 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ + AMX
Number of subjects: 51
Study 29653193 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT
Number of subjects: 51
Study 29653193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 26999504 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship program (8‐hr online program with 4 15‐min calls)
Number of subjects: 600
Study 24713632 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric diet (28-week program based on normal requirements for height and meal planning)
Number of subjects: 51
Study 24713632 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric diet
Number of subjects: 51
Study 24713632 — intervention group
Group type: COMPARATOR
Intervention: Free diet (control group)
Number of subjects: 51
Study 23097398 — intervention group
Group type: EXPERIMENTAL
Intervention: Large FSH dose (150 mg, n=18)
Number of subjects: 37
Study 23097398 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium FSH dose (130 mg, n=12)
Number of subjects: 37
Study 23097398 — intervention group
Group type: EXPERIMENTAL
Intervention: Small FSH dose (80 mg, n=7)
Number of subjects: 37
Study 23097398 — intervention group
Group type: COMPARATOR
Intervention: Control (saline, n=6)
Number of subjects: 37
Study 23097398 — intervention group
Group type: EXPERIMENTAL
Intervention: Large FSH (n=11)
Number of subjects: 37
Study 23097398 — intervention group
Group type: COMPARATOR
Intervention: Control (n=10)
Number of subjects: 37
Study 20504378 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (preemptive analgesia)
Number of subjects: 120
Study 20504378 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (postoperative analgesia)
Number of subjects: 120
Study 20504378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (preemptive analgesia)
Number of subjects: 120
Study 20504378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (postoperative analgesia)
Number of subjects: 120
Study 18400710 — intervention group
Group type: COMPARATOR
Intervention: 1 cup of black tea
Number of subjects: 20
Study 18400710 — intervention group
Group type: COMPARATOR
Intervention: 2 cups of black tea
Number of subjects: 20
Study 18400710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at molar ratio to iron 2:1
Number of subjects: 20
Study 18400710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at molar ratio to iron 4:1
Number of subjects: 20
Study 16618293 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Number of subjects: 60
Study 16618293 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3.0 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Number of subjects: 60
Study 16618293 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3.5 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Number of subjects: 60
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 10
Number of subjects: 967
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 50
Number of subjects: 967
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 100
Number of subjects: 967
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 400
Number of subjects: 967
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 1 month
Number of subjects: 967
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 6 months
Number of subjects: 967
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 1 year
Number of subjects: 967
Study 14667958 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 4 years
Number of subjects: 967
Study 10465703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating forefoot and rear foot zones separately
Number of subjects: 0
Study 10465703 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-stimulating forefoot and rear foot zones at different frequencies
Number of subjects: 0
Study 8896529 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 0
Study 8896529 — intervention group
Group type: COMPARATOR
Intervention: DTPw vaccine
Number of subjects: 0
Study 2010737 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 0
Study 2010737 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids
Number of subjects: 0
Study 7068935 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base (250 mg, four times a day for six days)
Number of subjects: 23
Study 7068935 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (250 mg, four times a day for six days)
Number of subjects: 23
Study 7068935 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (250 mg, four times a day for six days)
Number of subjects: 23
Study 7068935 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (control group, 250 mg, four times a day for six days)
Number of subjects: 23
Study 4061890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day (n = 20)
Number of subjects: 74
Study 4061890 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen or placebo (n = 54)
Number of subjects: 74
Study 29927496 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-strengthening intervention (10 weeks of relationship education services)
Number of subjects: 0
Study 29927496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no services)
Number of subjects: 0
Study 29927496 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-strengthening intervention
Number of subjects: 0
Study 27956763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunonutrition (IN)
Number of subjects: 244
Study 27956763 — intervention group
Group type: COMPARATOR
Intervention: Oral standard nutrition (Control)
Number of subjects: 244
Study 24783221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrarush therapy
Number of subjects: 22
Study 24783221 — intervention group
Group type: COMPARATOR
Intervention: Conventional preseasonal SIT
Number of subjects: 22
Study 22212646 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 μg vitamin D₃ (group 1)
Number of subjects: 97
Study 22212646 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 3000 μg vitamin D₃ (group 2)
Number of subjects: 97
Study 22212646 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-supplemented group)
Number of subjects: 97
Study 20974030 — intervention group
Group type: EXPERIMENTAL
Intervention: Belladonna and opium (B & O) suppository
Number of subjects: 99
Study 20974030 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 99
Study 18411239 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM
Number of subjects: 53
Study 18411239 — intervention group
Group type: EXPERIMENTAL
Intervention: Book
Number of subjects: 53
Study 18411239 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 53
Study 15605190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (800 mg daily for 2 years)
Number of subjects: 59
Study 12408892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (NEF) and desmethyl-nefopam (DMN) assayed using HPLC with a mobile phase of buffer and acetonitrile, flow rate 1.5 ml/min.
Number of subjects: 0
Study 10885083 — intervention group
Group type: EXPERIMENTAL
Intervention: Written agenda forms completed by patients
Number of subjects: 819
Study 7573921 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (EM/LIG) - EMLA and intradermal and subdermal 1% lignocaine infiltration
Number of subjects: 83
Study 7573921 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (EM/SAL) - EMLA and saline
Number of subjects: 83
Study 7573921 — intervention group
Group type: COMPARATOR
Intervention: Group C (PL/LIG) - Placebo cream and 1% lignocaine
Number of subjects: 83
Study 1976549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel tent preoperative treatment
Number of subjects: 629
Study 1976549 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 629
Study 7283035 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hydrogen peroxide
Number of subjects: 217
Study 7283035 — intervention group
Group type: COMPARATOR
Intervention: Control (no topical hydrogen peroxide)
Number of subjects: 217
Study 31379101 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of teriflunomide
Number of subjects: 14
Study 31379101 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of teriflunomide
Number of subjects: 14
Study 29545413 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ciclosporin A cationic emulsion (CsA CE)
Number of subjects: 734
Study 30072191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2) followed by FEC
Number of subjects: 152
Study 30072191 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by FEC
Number of subjects: 152
Study 30072191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2)
Number of subjects: 152
Study 30072191 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 152
Study 30072191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Number of subjects: 152
Study 26822209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin administered for 7 consecutive days
Number of subjects: 210
Study 26822209 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo administered for 7 consecutive days
Number of subjects: 210
Study 26822209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 210
Study 24961471 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of human fibrin sealant (Tisseel™, Baxter(®) Deerfield, IL, USA) sprayed along the suture line
Number of subjects: 100
Study 24961471 — intervention group
Group type: COMPARATOR
Intervention: No fibrin sealant
Number of subjects: 100
Study 22146491 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom A (F(ab')2 fragments)
Number of subjects: 100
Study 22146491 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom B (whole IgG molecules)
Number of subjects: 100
Study 20637495 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 20
Study 20637495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18198641 — intervention group
Group type: EXPERIMENTAL
Intervention: Aidi Injection (ADI) combined with FOLFOX4 regimen
Number of subjects: 117
Study 18198641 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 regimen alone
Number of subjects: 117
Study 16375790 — intervention group
Group type: EXPERIMENTAL
Intervention: Health technology assessment (HTA)
Number of subjects: 0
Study 16375790 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth evaluation
Number of subjects: 0
Study 16375790 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory strategy
Number of subjects: 0
Study 10673673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization chemotherapy
Number of subjects: 39
Study 10673673 — intervention group
Group type: COMPARATOR
Intervention: Ceprate SC selection
Number of subjects: 39
Study 9496390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 120 mg
Number of subjects: 52
Study 9496390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study 8347065 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow joint restriction using a splint
Number of subjects: 19
Study 8347065 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted elbow joint motion
Number of subjects: 19
Study 3519766 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide twice daily for 4 weeks
Number of subjects: 16
Study 3519766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 300 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 141
Study 30125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 600 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 141
Study 30125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 0 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 141
Study 30125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (all doses)
Number of subjects: 141
Study 30125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 141
Study 27232116 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression
Number of subjects: 100
Study 27232116 — intervention group
Group type: COMPARATOR
Intervention: CsA-based immunosuppression
Number of subjects: 100
Study 25945337 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (50 mcg every morning)
Number of subjects: 60
Study 25945337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23432361 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg day(-1)
Number of subjects: 67
Study 23432361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 22124043 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal membrane as a barrier
Number of subjects: 12
Study 22124043 — intervention group
Group type: COMPARATOR
Intervention: Control group (mucoperiosteal flap sutured back after debridement)
Number of subjects: 12
Study 18691337 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-PUFA supplementation (including DHA and AA)
Number of subjects: 901
Study 18691337 — intervention group
Group type: COMPARATOR
Intervention: Control group (formula milk without LC-PUFA)
Number of subjects: 901
Study 16533938 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (0.25 mg/kg bolus, followed by 0.125 microg/kg/min infusion for 12 hours, plus heparin, 70 U/kg)
Number of subjects: 2022
Study 16533938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo bolus and infusion for 12 hours, plus heparin bolus, 140 U/kg)
Number of subjects: 2022
Study 16533938 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2022
Study 16533938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2022
Study 14712149 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cleaning
Number of subjects: 114
Study 14712149 — intervention group
Group type: COMPARATOR
Intervention: Superficial cleaning (control)
Number of subjects: 114
Study 11155088 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 IU GH/m2/day
Number of subjects: 79
Study 11155088 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 IU GH/m2/day
Number of subjects: 79
Study 11155088 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 79
Study 9059953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg daily for 2 weeks) + calcium (500 mg daily for 11 weeks)
Number of subjects: 12
Study 9059953 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 12
Study 9059953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate + calcium
Number of subjects: 12
Study 8104201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 0
Study 8104201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3080726 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride predominant formula (46% medium-chain, 54% long-chain)
Number of subjects: 13
Study 3080726 — intervention group
Group type: COMPARATOR
Intervention: Long-chain fatty acid predominant formula (4% medium-chain, 96% long-chain)
Number of subjects: 13
Study 29528986 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent human papillomavirus vaccine (qHPV; types 6, 11, 16, 18)
Number of subjects: 575
Study 27683073 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic bone substitute (MBS) - 100% s-TCP
Number of subjects: 60
Study 27683073 — intervention group
Group type: COMPARATOR
Intervention: Biphasic bone substitute (BBS) - 60% HA and 40% s-TCP
Number of subjects: 60
Study 27683073 — intervention group
Group type: COMPARATOR
Intervention: Biphasic bone substitute (BBS)
Number of subjects: 60
Study 27683073 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic bone substitute (MBS)
Number of subjects: 60
Study 25634117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (4-12 mg/h)
Number of subjects: 70
Study 25634117 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 70
Study 22223124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity smoking cessation intervention
Number of subjects: 0
Study 22223124 — intervention group
Group type: COMPARATOR
Intervention: Medium-intensity smoking cessation intervention
Number of subjects: 0
Study 21371155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) with a selection box containing patch, gum, inhaler, sublingual tablet, oral pouch for 8 weeks after a week of familiarization.
Number of subjects: 1410
Study 21371155 — intervention group
Group type: COMPARATOR
Intervention: Usual Quitline care (control group).
Number of subjects: 1410
Study 18372218 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency exercise (3 endurance resistance exercises and cycle ergometer training for 30 min, 5 times a week for 8 months at 70% of VO(2max))
Number of subjects: 37
Study 18372218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 37
Study 17158427 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR‐alpha‐tocopheryl acetate
Number of subjects: 1
Study 17158427 — intervention group
Group type: EXPERIMENTAL
Intervention: all‐rac‐alpha‐tocopheryl acetate
Number of subjects: 1
Study 12659475 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐s isometric contraction (5‐IC)
Number of subjects: 43
Study 12659475 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐s isometric contraction (10‐IC)
Number of subjects: 43
Study 12659475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 11117766 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy
Number of subjects: 120
Study 11117766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy
Number of subjects: 120
Study 11117766 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Vaginal Hysterectomy
Number of subjects: 120